BUSINESS

• Sumitomo Dainippon’s FY2013 Payments to Healthcare Professionals at 13.1 Billion Yen
  October 1, 2014

• Kyowa Kirin, Pfizer to Collaborate on Cancer Immunotherapy
  October 1, 2014

• Kowa Receives Approval for Glaucoma Treatment Glanatec
  October 1, 2014

• AZ Was Concerned with Pfizer’s Possible Takeover Deal Withdrawal Due to US Anti-Inversion Move: CEO
  September 30, 2014

• e-Detailing Powerhouse M3 to Establish New Firm Dedicated to CSO Biz
  September 30, 2014

• Lixiana OK’d for Stroke Prevention in Japan: Daiichi Sankyo
  September 30, 2014

• Daiichi Sankyo to Buy US Biotech Ambit, Beef Up Oncology Portfolio
  September 30, 2014

• Kyowa Kirin’s Neutropenia Treatment G-Lasta Approved
  September 30, 2014

• JCR Files NDA for Japan’s 1st Cell-Based Drug JR-301
  September 30, 2014

• Sumitomo Dainippon, SanBio to Jointly Develop Cell Therapy Agent for Chronic Stroke in North America
  September 30, 2014

• Ixekizumab Improves Skin Lesions in Japanese Psoriasis Patients: Eli Lilly Japan
  September 30, 2014

• Avigan Administered to Ebola-Infected French Woman: Fujifilm
  September 29, 2014

• Sanofi’s 2013 Payments to Healthcare Professionals Down 11%
  September 29, 2014

• Novartis Files Panobinostat for Multiple Myeloma in Japan
  September 29, 2014

• Sanofi Opens Asia Pacific Development Hub in Shanghai
  September 29, 2014

• Ribomic Goes Public, Aims to Swing to Black on Aptamers
  September 26, 2014

• NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
  September 26, 2014

• Takeda to Invest 2.5 Billion Yen in US Firm for New Drug Development
  September 26, 2014

• OncoTherapy Science Appoints Masaharu Mori, Formerly of Shionogi and Novartis Pharma, as New President
  September 26, 2014

• Eisai Sets Up Director Position for Pariet
  September 26, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 528
• 529
• 530
• 531
• 532
• 533
• 534
• 535
• 536
• …
• Next ›
• 最終 »